XORTX Therapeutics (XRTX) Revenue (2022 - 2023)
XORTX Therapeutics (XRTX) posted Revenue of -$1.6 million for Q4 2023, down 259.38% on a QoQ basis from $994598.3 in Q3 2023, and down 173.74% year-over-year from $2.1 million in Q4 2022.
XORTX Therapeutics (XRTX) Revenue (2022 - 2023) Analysis & Trends
XORTX Therapeutics' Revenue history runs 2 years deep, the most recent figure standing at -$1.6 million for Q4 2023.
- Quarterly Revenue fell 173.74% year-over-year to -$1.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (down 67.21% YoY) and the FY2023 annual result came in at $2.0 million, up 0.84% from the prior year.
- Revenue was -$1.6 million for Q4 2023 at XORTX Therapeutics, down from $994598.3 in the prior quarter.
- Across five years, Revenue topped out at $2.1 million in Q4 2022 and bottomed at -$1.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | XORTX Therapeutics | 2.80 Bn | 2.80 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | 994,598.33 |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | 2.15 Mn |
| Sep 30, 2022 | 917,922.54 |
| Jun 30, 2022 | 971,672.58 |
| Mar 31, 2022 | 2.13 Mn |